Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19

COVID-19 Clinical Trial

Official title:

Prospective Descriptive Study on the Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04341766
• Other study ID #: COVID-ECHO
• Status: Completed
• Start date: March 31, 2020
• Est. completion date: June 30, 2020

Study information

• Verified date: July 2020
• Source: Centre Hospitalier Intercommunal Creteil
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Clinical thoracic ultrasound plays an important role in the exploration, diagnosis and follow-up of thoracic pathologies.

The COVID (Coronavirus Disease) epidemic is leading to a large influx of patients in the emergency department with respiratory disorders. The rapid diagnosis of respiratory disorders in infected patients is important for further management.

Chest ultrasound has already demonstrated its value in the diagnosis of pneumonia in the emergency department with superiority over chest X-ray.

However, there is little data on the thoracic ultrasound semiology of viral pneumonia in general and of COVID in particular.

Description:

Chest ultrasound has already shown its value in the diagnosis of pneumonia in the emergency department with superiority over chest X-ray.

However, there is little data on the thoracic ultrasound semiology of viral pneumonia in general and of COVID in particular.

Peng reported data from 20 patients and compared them to chest CT. The abnormalities are a thickening of the pleuropneumonia line, an interstitial syndrome with B lines, corresponding to frosted glass opacities, confluent B lines (snowstorm appearance) corresponding to interstitial infiltrate, sub-pleural alveolar opacities corresponding to sub-pleural condensations, more frank alveolar images corresponding to alveolar opacities. A multifocal aspect was associated with involvement of more than 2 lobes. However, the frequency of these abnormalities as well as the sensitivity of the echo are not detailed in this article.

Another Italian article describes a clinical case of COVID-19 pneumonia with sub-pleural involvement and irregularity of the pleuro-pulmonary line.

Clinical thoracic ultrasound has a major potential interest during the COVID epidemic:

available at the patient's bedside, avoiding the need to move around, feasible for the physician during his visit, easy to clean especially if ultraportable devices are used, fast and not exposing the staff any more than the usual clinical examination.

In order to determine whether this technique is useful in the management of infected patients or patients suspected of COVID-19 infection with respiratory signs, we propose a descriptive prospective study evaluating the ultrasound semiology of COVID-19 pneumonia and the interest of ultrasound in the evolutionary follow-up of these patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 106
• Est. completion date: June 30, 2020
• Est. primary completion date: May 27, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 105 Years

Eligibility

Inclusion Criteria:

• Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan

Exclusion Criteria:

• Patient not agreeing to have his or her data collected for the study

• Unconscious patient

Related Conditions & MeSH terms

• COVID-19
• Pneumonia
• Pneumonia, Viral

Intervention

Other:
• No special intervention
No special intervention : Ultrasound data will be collected

Locations

Country	Name	City	State
France	CHU Amiens	Amiens
France	CH de la Côte Basque	Bayonne
France	CHU Ambroise Paré	Boulogne-Billancourt
France	CHU Caen	Caen
France	CHG de Chambery	Chambéry
France	Centre Hospitalier Intercommunal de Créteil	Créteil
France	CHU de Limoges	Limoges
France	APHM - Hopital Nord	Marseille
France	CHU de Nancy	Nancy
France	CHU Nîmes	Nîmes
France	CHR Orléans	Orléans
France	CHU Cochin	Paris
France	CHU Poitiers	Poitiers
France	CHU Rouen	Rouen
France	CH Saint-Quentin	Saint-Quentin
France	CHU Larrey - Toulouse	Toulouse
France	CHU de Tours	Tours

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Intercommunal Creteil

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characteristics of pulmonary ultrasound for Covid-19 patients	description of ultrasound abnormalities for Covid-19 patients	Day one
Secondary	Characteristics of pulmonary ultrasound for Covid-19 patients	description of ultrasound abnormalities for Covid-19 patients	Day 3
Secondary	Characteristics of pulmonary ultrasound for Covid-19 patients	description of ultrasound abnormalities for Covid-19 patients	Day 14
Secondary	Charateristics of pulmonary CT-scan for Covid-19 patients	description of CT-scan abnormalities for Covid-19 patients	Day 1
Secondary	Charateristics of pulmonary CT-scan for Covid-19 patients	description of CT-scan abnormalities for Covid-19 patients	Day 3
Secondary	Charateristics of pulmonary CT-scan for Covid-19 patients	description of CT-scan abnormalities for Covid-19 patients	Day 14